The 46 references in paper D. Naskhletashvili R., V. Gorbunova A., A. Bekyashev Kh., V. Karakhan B., E. Moskvina A., E. Prozorenko V., Д. Насхлеташвили Р., В. Горбунова А., А. Бекяшев Х., В. Карахан Б., Е. Москвина А., Е. Прозоренко В. (2015) “РОЛЬ ТАРГЕТНОЙ ТЕРАПИИ В КОМПЛЕКСНОМ ЛЕЧЕНИИ БОЛЬНЫХ РАКОМ ПОЧКИ С МЕТАСТАТИЧЕСКИМ ПОРАЖЕНИЕМ ГОЛОВНОГО МОЗГА // ROLE OF TARGETED THERAPY IN THE COMBINATION TREATMENT OF PATIENTS WITH KIDNEY CANCER AND METASTATIC BRAIN INVOLVEMENT” / spz:neicon:ogsh:y:2012:i:4:p:19-25

1
Ammirati M., Cobbs C.S., Linskey M.E. et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:85−96.
(check this in PDF content)
2
Besse B., Lasserre S.F., Compton P. et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010;16:269−78.
(check this in PDF content)
3
Choueiri T.K., Duh M.S., Clement J. et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 2009;105:1247−54.
(check this in PDF content)
4
Culine S., Bekradda M., Kramar A. et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 1998;83:2548−53.
(check this in PDF content)
5
Dalhaung A., Haukland E., Nieder C. Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib. World J Surg Oncol 2010;8:36.
(check this in PDF content)
6
Elfiky A.A., Cho D.C., McDermott D.F. et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear cell renal carcinoma. Urol Oncol 2010; doi:10.1016/j. urolonc.2010.01.008; [Epub ahead of print].
(check this in PDF content)
7
Escudier B., Bellmut J., Negrier S. et al. Phase III trial of bevacizumab plus interferon alpha-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144−50.
(check this in PDF content)
8
Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cell cancer global evaluation trial. J Clin Oncol 2009;27:3312−8.
(check this in PDF content)
9
Feldman D.R., Baum M.S., Ginsberg M.S. et al. Phase 1 trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. Genitourinary Cancer 2009;27:1432−9.
(check this in PDF content)
10
Gleave M.E., Elhilali M., Fradet Y. et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. New Engl J Med 1998;338:1265−71.
(check this in PDF content)
11
Gore M.E., Hariharan S., Porta C. et al. Sunitinib in metastatic renal carcinoma patients with brain metastases. Cancer 2011; 117:501−9.
(check this in PDF content)
12
Guirgis L.M., Yang J.C., White D.E. et al. Safety and efficacy of high dose IL-2 therapy in patients with brain metastasis. J Immunother 2002;25:82−7.
(check this in PDF content)
13
Haznedar J., Patyna S., Bello C.L. et al. Single and multiple dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 2009;64:691−706.
(check this in PDF content)
14
Helgason H.H., Mallo H.A., Droogendijk H. et al. Brain metastases in patients with renal cell cancer new targeted treatment. J Clin Oncol 2008;26:152−4.
(check this in PDF content)
15
Hu S., Chen Z., Franke R. et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15:6062−9.
(check this in PDF content)
16
Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alpha, or both for advanced renal cell carcinoma. New Engl J Med 2007;456:2271−81.
(check this in PDF content)
17
Iwamoto F.M., Lamborn K.R., Robins I.H. et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06−02). Neuro Oncol 2010;12:855−61.
(check this in PDF content)
18
Kim A., McCully C., Cruz R. et al. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Invest New Drugs 2010; doi:10.1007/s10637-010-9585-1; [Epub ahead of print].
(check this in PDF content)
19
Kirchner H., Strumberg D., Bahl A. et al. Patient based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:585−96.
(check this in PDF content)
20
Kuhn J.G., Chang S.M., Wen P.Y. et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 2007;13:7401−6.
(check this in PDF content)
21
Lagas J.S., van Waterschoot R.A., Sparidans R.W. et al. Breast cancer resistance protein and p-glycoprotein limit sorafenib brain accumulation. Molec Cancer Ther 2010;9:319−26.
(check this in PDF content)
22
Larkin J., Gore M. Is advanced renal cell carcinoma becoming a chronic disease? Lancet 2010;376:574−5.
(check this in PDF content)
23
Lukas R.V., Chmura S., Nicholas M.K. Management of central nervous system metastases from renal cancer. Emerg Cancer Therap 2011;2:157−68.
(check this in PDF content)
24
Massard C., Zonierek J., Gross-Goupil M. et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010; 21:1027−31.
(check this in PDF content)
25
Medioni J., Cojocarasu O., Belcaceres J.L. et al. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 2007;18:1282−3.
(check this in PDF content)
26
Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alpha in metastatic renal cell carcinoma. New Engl J Med 2007;356:115−24.
(check this in PDF content)
27
Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256−65.
(check this in PDF content)
28
Muacevic A., Siebels M., Tonn J.C. et al. Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or surgery? World J Urol 2005;23:180−4.
(check this in PDF content)
29
Muldoon L.L., Soussain C., Jahnke K. et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007;25:2295−305.
(check this in PDF content)
30
Murata J.I., Sawamura Y., Terasaka S. et al. Complete response of a large brain metastasis of renal cell cancer to interferon-alpha: case report. Surg Neurol 1999;51:289−91.
(check this in PDF content)
31
Nicholas M.K., Lukas R. Immunologic privilege and the brain. In: Arnason B.G., ed. NeuroImmune Biology: The Brain and Host Defense, Vol. 9. London, UK: Elsevier; 2010. P. 169−181.
(check this in PDF content)
32
O’Reilly T., McSheehy P., Kawai R. et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 2010;54:625−39.
(check this in PDF content)
33
Ranze O., Hoffman E., Distelrath A. et al. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie 2007; 30:450−1.
(check this in PDF content)
34
Saitoh H. Distant metastases from renal carcinoma. Cancer 1988;48:1487−91.
(check this in PDF content)
35
Samlowski W.E., Majer M., Boucher K.M. et al. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer 2008; 113:2539−48.
(check this in PDF content)
36
Shuch B., LaRochelle J.C., Klatte T. et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008;113;1641−8.
(check this in PDF content)
37
Shukla S., Robey R.W., Bates S.E. et al. Sunitinib (Sutent, SU11248), a smallmolecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters p-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009; 37:359−65.
(check this in PDF content)
38
Sperduto P.W., Chao S.T., Sneed P.K. et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 2010; 77:655−61.
(check this in PDF content)
39
Stadler W.M., Figlin R.A., McDermott D.F. et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272−9.
(check this in PDF content)
40
Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061−8.
(check this in PDF content)
41
Thibault F., Billemont B., Rixe O. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J Neurooncol 2008;86:243−4.
(check this in PDF content)
42
Valcamonico F., Ferrari V., Amoroso V. et al. Long lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 2009; 91:47−50.
(check this in PDF content)
43
Vogl U.M., Bojic M., Lamm W. et al. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. BMC Cancer 2010;10:480.
(check this in PDF content)
44
Vredenburgh J.J., Cloughesy T., Samant M. et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 2010;15:1329−34.
(check this in PDF content)
45
Yamanaka K., Gohji K., Hara I. et al. Clinical study of renal cell carcinoma with brain metastasis. Int J Urol 1998;5:124−8.
(check this in PDF content)
46
Zeng H., Li X., Yao J. et al. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. Urol Int 2009;83:482−5.
(check this in PDF content)